Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Operating Income (2022 - 2026)

Centessa Pharmaceuticals has reported Operating Income over the past 4 years, most recently at -$68.5 million for Q4 2025.

  • Quarterly Operating Income rose 8.19% to -$68.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$207.7 million through Dec 2025, down 3.3% year-over-year, with the annual reading at -$207.7 million for FY2025, 3.3% down from the prior year.
  • Operating Income was -$68.5 million for Q4 2025 at Centessa Pharmaceuticals, down from -$53.8 million in the prior quarter.
  • Over five years, Operating Income peaked at -$30.8 million in Q1 2025 and troughed at -$74.6 million in Q4 2024.
  • The 4-year median for Operating Income is -$47.9 million (2023), against an average of -$49.5 million.
  • Year-over-year, Operating Income surged 31.27% in 2023 and then tumbled 112.01% in 2024.
  • A 4-year view of Operating Income shows it stood at -$41.6 million in 2022, then grew by 15.44% to -$35.2 million in 2023, then crashed by 112.01% to -$74.6 million in 2024, then rose by 8.19% to -$68.5 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Operating Income are -$68.5 million (Q4 2025), -$53.8 million (Q3 2025), and -$54.7 million (Q2 2025).